RARE Market Cap History



Below is a table of the RARE market cap history going back to 1/31/2014:

Date RARE Market Cap
1/31/20141.19B
3/14/20141.80B
5/7/20141.06B
8/6/20141.59B
11/3/20141.43B
3/23/20152.13B
5/6/20152.32B
8/7/20154.24B
11/4/20154.22B
2/19/20162.47B
5/4/20162.46B
8/3/20162.56B
11/3/20162.15B
2/13/20173.12B
5/1/20172.68B
7/24/20173.04B
10/30/20171.92B
2/15/20182.36B
5/3/20182.62B
7/30/20183.89B
10/30/20182.50B
2/14/20192.84B
5/1/20193.69B
7/26/20193.59B
8/28/20191.11B
10/31/20192.32B
2/10/20203.55B
5/1/20203.50B
7/27/20204.93B
10/22/20205.61B
2/8/202111.10B
4/30/20217.53B
7/28/20215.52B
10/28/20215.78B
2/10/20224.95B
5/2/20225.06B
7/25/20223.57B
10/28/20222.86B
2/13/20233.08B
5/1/20233.12B
7/31/20233.08B
10/30/20232.72B
2/15/20243.81B
4/26/20243.68B

Also see: RARE Shares Outstanding History
and RARE YTD Return
RARE Historical Market Cap:
+11.66% CAGR
RARE Historical Market Cap: +11.66% CAGR

Mouse over chart for data details
1/31/2014 ...4/26/2024
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia. We show 44 historical shares outstanding datapoints in our RARE shares outstanding history coverage, used to compute RARE market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing RARE market cap history over the course of time is important for investors interested in comparing RARE's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of RARE versus a peer is one thing; comparing RARE market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like RARE can fluctuate over the course of history. With this page we aim to empower investors researching RARE by allowing them to research the RARE market cap history.
Quotes delayed 20 minutes

Email EnvelopeFree RARE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ultragenyx Pharmaceutical (RARE) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

RARX Market Cap History
RBOT Market Cap History
RCEL Market Cap History
RCKT Market Cap History
RCUS Market Cap History
RDHL Market Cap History
RDNT Market Cap History
RDY Market Cap History
REGN Market Cap History
RENB Market Cap History
More Healthcare companies »

 

RARE Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.